Celltrion has been re-certified with the highest grade of 'AAA' in the Customs AEO (Authorized Economic Operator) program.
On July 14, Celltrion announced that it received the AAA certification for both export and import sectors during a ceremony held at the Incheon Customs Headquarters. This re-certification ensures that Celltrion will maintain its AAA status until 2030.
The AEO certification is awarded by the Customs Service based on a comprehensive review of compliance with regulations, internal control systems, financial soundness, and safety management, in accordance with international standards set by the World Customs Organization (WCO). Among the 773 companies currently certified as AEO, only 20 hold the AAA grade, with Celltrion being the sole company in the pharmaceutical and biopharmaceutical sector.
Celltrion was recognized during the re-certification process for continuously enhancing its internal control and safety management systems. The company operates a supply chain management system linked with overseas logistics partners and has established an integrated self-inspection system to pre-check compliance with free trade agreements (FTAs) and customs legality.
This system was previously highlighted as a best practice to the UK Customs during the Korea-UK AEO Mutual Recognition Agreement (MRA) collaboration process.
Maintaining the AAA grade allows Celltrion to continue benefiting from customs administration advantages, such as exemptions from submitting import and export documentation, logistics inspections, and expedited customs clearance. The company expects to reduce customs clearance times for biopharmaceuticals and continue to enjoy expedited clearance benefits in the U.S., Japan, and the UK, where it has signed AEO mutual recognition agreements.
Kang Seong-hwan, Head of Supply Chain Operations at Celltrion, stated, "Maintaining the AAA grade reaffirms our customs process and risk management capabilities. We will strive to operate a stable global supply chain and ensure timely delivery of pharmaceuticals based on our customs competitiveness."
In addition, Celltrion recently announced its preliminary earnings, reporting a record quarterly revenue of 1.3 trillion won and an operating profit of 430 billion won for the second quarter of this year. The company attributed this growth to an increased share of high-revenue new biosimilar sales.
Building on the profitability secured from its existing biosimilar business, Celltrion aims to expand its next-generation product portfolio while investing in the development of new drugs, including antibody-drug conjugates (ADCs), multi-antibodies, and obesity treatments, to diversify its growth avenues.
On July 14, Celltrion announced that it received the AAA certification for both export and import sectors during a ceremony held at the Incheon Customs Headquarters. This re-certification ensures that Celltrion will maintain its AAA status until 2030.
The AEO certification is awarded by the Customs Service based on a comprehensive review of compliance with regulations, internal control systems, financial soundness, and safety management, in accordance with international standards set by the World Customs Organization (WCO). Among the 773 companies currently certified as AEO, only 20 hold the AAA grade, with Celltrion being the sole company in the pharmaceutical and biopharmaceutical sector.
Celltrion was recognized during the re-certification process for continuously enhancing its internal control and safety management systems. The company operates a supply chain management system linked with overseas logistics partners and has established an integrated self-inspection system to pre-check compliance with free trade agreements (FTAs) and customs legality.
This system was previously highlighted as a best practice to the UK Customs during the Korea-UK AEO Mutual Recognition Agreement (MRA) collaboration process.
Maintaining the AAA grade allows Celltrion to continue benefiting from customs administration advantages, such as exemptions from submitting import and export documentation, logistics inspections, and expedited customs clearance. The company expects to reduce customs clearance times for biopharmaceuticals and continue to enjoy expedited clearance benefits in the U.S., Japan, and the UK, where it has signed AEO mutual recognition agreements.
Kang Seong-hwan, Head of Supply Chain Operations at Celltrion, stated, "Maintaining the AAA grade reaffirms our customs process and risk management capabilities. We will strive to operate a stable global supply chain and ensure timely delivery of pharmaceuticals based on our customs competitiveness."
In addition, Celltrion recently announced its preliminary earnings, reporting a record quarterly revenue of 1.3 trillion won and an operating profit of 430 billion won for the second quarter of this year. The company attributed this growth to an increased share of high-revenue new biosimilar sales.
Building on the profitability secured from its existing biosimilar business, Celltrion aims to expand its next-generation product portfolio while investing in the development of new drugs, including antibody-drug conjugates (ADCs), multi-antibodies, and obesity treatments, to diversify its growth avenues.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.